title: Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification.
abstract: Mouse P19 embryonal carcinoma cells in aggregation culture in the presence of 10(-6) M retinoic acid followed by monolayer culture differentiate into nerve and glial cells. In this study, we demonstrated that the neurofilament-L (NF-L) mRNA and protein levels of these cells were enhanced in accordance with their retinoic acid-induced neural differentiation. Okadaic acid (OA) treatment of the cells markedly suppressed this differentiation-dependent NF-L gene expression increase and neurite outgrowth of the cells. Similar results were obtained when tautomycin was used instead of OA, suggesting that inhibition of protein phosphatase(s) is involved in the suppression of neural differentiation. OA treatment did not affect the NF-L gene transcription level, determined by the nuclear run-on transcription assay, but it did reduce the stability of both the 3.5- and 2.3-kilobase NF-L mRNAs. The expression and activity levels of protein phosphatase 2A (PP2A) and 2B (PP2B) but not protein phosphatase 1 (PP1) in P19 cells increased in accordance with the enhanced NF-L gene expression. The presence of OA in the culture medium during the course of the neural differentiation caused a reduced PP2A activity but not PP1 and PP2B activities of the cell extracts. On the other hand, both PP1 and PP2B activities but not PP2A activity of cell extracts were suppressed by the addition of cyclosporin A or FK506 in the culture medium. However, both cyclosporin A and FK506 treatments affected neither NF-L gene expression nor neurite outgrowth. These results demonstrate that the OA treatment inhibits the differentiation-dependent increase in NF-L gene expression by destabilizing its mRNAs and suggest that PP2A plays key roles in the differentiation-dependent enhanced expression of the NF-L gene and is the point of the action of OA.
authors.affiliation: Department of Biochemistry, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Sasahara
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Onodera
authors.forename: M
authors.initials: M
authors.lastname: Onoda
authors.forename: M
authors.initials: M
authors.lastname: Ohnishi
authors.forename: S
authors.initials: S
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Kusuda
authors.forename: H
authors.initials: H
authors.lastname: Shima
authors.forename: M
authors.initials: M
authors.lastname: Nagao
authors.forename: H
authors.initials: H
authors.lastname: Abe
authors.forename: Y
authors.initials: Y
authors.lastname: Yanagawa
authors.forename: A
authors.initials: A
authors.lastname: Hiraga
authors.forename: S
authors.initials: S
authors.lastname: Tamura
mesh_terms: D000818:Animals; D018236:Carcinoma, Embryonal; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D016572:Cyclosporine / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D018507:Gene Expression Regulation, Developmental; D051379:Mice; D016900:Neurofilament Proteins / Q000235:genetics*; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D019319:Okadaic Acid / Q000494:pharmacology*; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D011499:Protein Processing, Post-Translational; D012333:RNA, Messenger / Q000378:metabolism; D016559:Tacrolimus / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D016900:Neurofilament Proteins; D012333:RNA, Messenger; C044882:neurofilament protein L; D019319:Okadaic Acid; D016572:Cyclosporine; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D016559:Tacrolimus